|
|
|
| Efficacy and Safety of Quetiapine Joint Midazolam in the Treatment of Alzheimer's Disease with Sleep Disturbance |
| QIU Zheng, HE Bi- hua, LIN Li |
| Department of Neurology, Third People's Hospital of Hubei Province, Wuhan Hubei 430033 |
|
|
|
|
Abstract 【Objective】To explore the more effective and safe way of quetiapine combined with midazolam in the treatment of Alzheimer's disease with sleep disturbance. 【Methods】A total of 127 patients with AD and sleep dysfunction were randomly divided into the observation group (n+65) and the control group (n=62). Patients in control group received quetiapine alone, while quetiapine plus midazolam were treated in the observation group. To Clinical efficacy and adverse effect between two groups were compared. 【Results】After 4 weeks of treatment, the total effective rate in the observation group was 96.92% (63/65), which was significantly higher than 80.65% (50/62) in the control group, and the difference was statistically significant (χ2=8.57, P<0.05). After 8 weeks of treatment, the total effective rate of the observation group was 100.00% (65/65), which was significantly higher than 87.10% (54/62) of the control group, and the difference was statistically significant (χ2=8.95, P<0.05). Before treatment, there were no statistically significant differences in the PSQI scores of sleep quality, time to fall asleep, daytime function, sleep disorder, sleep time, sleeping drugs, and total scores between the two groups of patients (all P>0.05). After 4 weeks and 8 weeks of treatment, the observation group's PSQI scores for sleep quality, time to fall asleep, daytime function, sleep time, sleeping drugs and other scores and total scores were significantly lower than those of the control group; And the differences were statistically significant (both P<0.05). However, there was no statistically significant difference in sleep disorder scores between the two groups (P>0.05). The total incidence of adverse reactions in the observation group was 3.07% (2/65), which was significantly lower than 14.52% (9/62) in the control group, and the difference was statistically significant (χ2=5.249, P=0.028).【Conclusion】Quetiapine combined with midazolam in the treatment of Alzheimer's disease with sleep disturbance was more effective and safer than singular quetiapine treatment and it was worth of application.
|
|
Received: 07 May 2021
|
|
|
|
|
|
[1] 邱海鹏,张晓璇,马征,等.奥氮平和喹硫平对阿尔兹海默病患者吞咽功能的影响分析[J].中国生化药物杂志,2015,35(9):130-132.
[2] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.
[3] 杨红,朱德生.盐酸多奈哌齐治疗老年痴呆的疗效研究[J].中国全科医学,2013,16(8):853-856.
[4] 董冰,程媛. 观察采用喹硫平治疗老年痴呆精神行为症状的疗效[J].中华老年心血管病杂志,2016,4(9):146-147.
[5] 刘俊骞,吕俊丽,张赛,等.对轻度认知障碍和痴呆患者睡眠障碍管理的推荐[J].中华老年心脑血管病杂志,2015,17(7):779-782.
[6] 王云红.喹硫平合并小剂量丙戊酸钠治疗老年期痴呆精神行为症状研究[J].中国卫生产业, 2014(6):78-80.
[7] 马文斌.喹硫平与氟哌啶醇治疗老年痴呆患者精神行为症状的对照研究[J].中国医院用药评价与分析,2015,15(3):379-380.
[8] 冯鹏程,刘勤俭,宁红晖,等.控制血压血糖预防老年痴呆前瞻性观察研究[J].内科,2016,11(6):823-824.
[9] 陈妮,张彩华.老年痴呆患者走失行为的研究进展[J].护理学杂志,2013,28(1):88-91.
[10] 刘云,吴晓球.老年痴呆症危险因素的研究进展[J].医学综述,2016,22(12):2349-2352.
[11] SANDER M C,WERKLE-BERGNER M,GERJETS P,et al.The two-component model of memory development,and its potential implications for educational settings[J].Dev Cogn Neurosci,2012(2 Suppl 1):S67-S77.
[12] 付旭,刘盈,秦晓霞.喹硫平与利培酮治疗躁狂症的效果比较[J].中国医药导报,2016,13(14):123-125.
[13] 李韧之,赵淑娟.喹硫平治疗老年精神分裂症的对照观察[J].现代医药卫生,2011,27(6):841-842.
[14] 张洁, 姚杨城. 咪达唑仑复合芬太尼在纤维支气管镜检查中的应用[J].黑龙江医药, 2012, 25(2): 283-285.
[15] 张红, 王丽娜. 咪达唑仑复合芬太尼与丙泊酚用于无痛胃肠镜检查的研究[J].中国生化药物杂志, 2015,35(9):112-114.
[16] 项瑛, 叶伟娣, 孙娜, 等. 地佐辛联合咪达唑仑在玻璃体切割术中镇痛和镇静效果的评价[J].上海医学, 2016,39(2):89-93.
[17] 王春艳,谢丹,曾星,等.麻醉前使用右美托咪定或咪达唑仑临床效果的比较[J].临床麻醉学杂志,2013,29(6):548-550.
[18] 吴斌.喹硫平与利培酮治疗老年痴呆精神行为障碍对照研究[J].中国健康心理学杂志,2012,20(11):1613-1614.
[19] 严茜茜,黄罗仪,王朝杰,等. 五种治疗阿尔茨海默病药物分子结构与性质的密度泛函计算分析[J].温州医科大学学报,2020,50(12):955-960.
[20] 肖飞. 瑞舒伐他汀联合盐酸多奈哌齐治疗阿尔茨海默病患者的效果[J].中国药物经济学,2020,15(12):96-98.
|
|
|
|
2021, Vol. 38 
